Benzinga · May 13, 2026
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.
NK
NASDAQ · NKTX
Nkarta, Inc. Common Stock
Healthcare · Biotechnology
$2.31
Down-$0.22 (-8.70%)
Updated Oct 7, 2026, 10:38 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 133.54M
- P/E ratio
- -1.27
- Dividend yield
- 0.00%
- 52-week range
- $1.96 – $3.72
- Volume
- 754.8K
- Avg. volume
- 912.63K
Price performance · NKTX
NKTX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
NKTX closed at $2.31 after 21 trading sessions, down 28.48% for the selected period.
- Last close
- $2.31
- Period change
- -28.48%
- Period low
- $2.31
- Period high
- $3.23
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.55 | $2.55 | $2.295 | $2.31 | 754.8K |
| Oct 5, 2026 | $2.57 | $2.57 | $2.45 | $2.53 | 522.11K |
| Oct 2, 2026 | $2.60 | $2.625 | $2.52 | $2.575 | 366.78K |
| Oct 1, 2026 | $2.59 | $2.67 | $2.545 | $2.56 | 402.3K |
| Sep 30, 2026 | $2.65 | $2.69 | $2.55 | $2.62 | 283.16K |
| Sep 29, 2026 | $2.68 | $2.68 | $2.53 | $2.62 | 524.59K |
| Sep 28, 2026 | $2.75 | $2.7852 | $2.67 | $2.67 | 810.74K |
| Sep 25, 2026 | $2.86 | $2.86 | $2.725 | $2.75 | 681.13K |
| Sep 24, 2026 | $2.72 | $2.89 | $2.585 | $2.85 | 933.92K |
| Sep 23, 2026 | $2.91 | $2.99 | $2.615 | $2.76 | 1.09M |
| Sep 22, 2026 | $2.92 | $2.985 | $2.865 | $2.95 | 415.56K |
| Sep 21, 2026 | $2.87 | $2.91 | $2.8009 | $2.88 | 385.79K |
| Sep 18, 2026 | $2.81 | $2.885 | $2.79 | $2.83 | 609.74K |
| Sep 17, 2026 | $2.93 | $2.968 | $2.745 | $2.81 | 531.5K |
| Sep 16, 2026 | $2.93 | $3.065 | $2.825 | $2.87 | 642.15K |
| Sep 15, 2026 | $2.92 | $2.95 | $2.785 | $2.88 | 458.38K |
| Sep 14, 2026 | $2.92 | $3.08 | $2.865 | $2.92 | 491.73K |
| Sep 11, 2026 | $2.85 | $3.00 | $2.8399 | $2.91 | 487.41K |
| Sep 10, 2026 | $2.88 | $2.88 | $2.755 | $2.81 | 559.28K |
| Sep 9, 2026 | $3.19 | $3.20 | $2.86 | $2.91 | 784.6K |
| Sep 8, 2026 | $2.86 | $3.30 | $2.8001 | $3.23 | 1.47M |
Latest NKTX news
The latest Smart Investors Daily articles mentioning NKTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NKTX research
Overview
Company profile and research snapshot.
Company profile
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $21.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Stifel | Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Needham | Buy | — |
| Mar 31, 2026 | Mizuho | Outperform | — |
| Mar 26, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · May 12, 2026
Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances
Nkarta (NKTX) Q1 loss of $0.37 beat estimates. Cash runway extended into 2029 as NKX019 autoimmune trials advance with initial data expected in 2026.
Benzinga · May 12, 2026
Nkarta Q1 EPS $(0.37), Inline
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.
Finnhub · May 12, 2026
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
